4-(2-硝基苯基磺酰基)吗啉 | 99069-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-硝基苯基磺酰基)吗啉
• 英文名称: 2-nitrobenzenesulfomorpholide
• 英文别名: 4-(2-nitrophenylsulfonyl)morpholine；4-(2-nitrobenzenesulfonyl)morpholine；4‐(2‐nitrobenzenesulfonyl)morpholine；4-(2-Nitro-benzolsulfonyl)-morpholin；4-(2-nitrophenyl)sulfonylmorpholine
• CAS: 99069-26-8
• 化学式: C₁₀H₁₂N₂O₅S
• mdl: MFCD00514601
• 分子量: 272.282
• InChiKey: NXJKHLDWXHCTMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-硝基苯基磺酰基)吗啉 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 生成 4-[(2-氨基苯基)磺酰基]吗啉
  参考文献：
  名称：

  酰胺和磺酰胺取代的N-芳基6-氨基喹喔啉类化合物作为具有改进的理化性质的PFKFB3抑制剂的合成。

  摘要：

  在肿瘤学中，“ Warburg效应”描述了癌细胞中糖酵解产生的能量增加。普遍存在且缺氧诱导的6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶3（PFKFB3）在通过产生果糖-2,6-二磷酸（F-2,6- BP），一种限制糖酵解速率的磷酸果糖激酶PFK-1的有效活化剂。合成了一系列基于N-芳基6-氨基喹喔啉骨架的酰胺和磺酰胺衍生物，并在体外通过生化测定以及在HCT116细胞中测试了它们对PFKFB3的抑制作用。羧酰胺系列显示出令人满意的动力学溶解度和代谢稳定性，并且在该类别中，已鉴定出具有低纳摩尔活性的强效铅化合物，并具有适合进一步体内评估的合适特征。

  DOI：

  10.1016/j.bmcl.2018.12.034
• 作为产物：
  描述：

  邻硝基苯磺酰氯 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 15.0h， 生成 4-(2-硝基苯基磺酰基)吗啉
  参考文献：
  名称：

  Acylating and arylsulfonylating ability of O-derivatives of isatin 3-oximes

  摘要：

  DOI：

  10.1007/s10593-005-0114-7

文献信息

• [EN] SUBSTITUTED QUINOXALINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOXALINE SUBSTITUÉS
  申请人：SELVITA S A

  公开号：WO2016180537A1

  公开（公告）日：2016-11-17

  The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

  这项发明涉及取代喹喔啉衍生物。这些化合物对预防和/或治疗包括过度增殖性疾病在内的多种医疗状况具有用处。
• Metal-free synthesis of sulfonamides via iodine-catalyzed oxidative coupling of sulfonyl hydrazides and amines
  作者：Santosh Kumar Reddy Parumala、Rama Krishna Peddinti

  DOI：10.1016/j.tetlet.2016.02.009

  日期：2016.3

  A novel, rapid, and environmentally-friendly protocol for the synthesis of sulfonamides using iodine as catalyst under solvent-free conditions is described. This method involves the oxidative coupling of sulfonyl hydrazides and amines in the presence of catalytic amount of iodine using TBHP as oxidant. This protocol does not require purification techniques such as column chromatography and recrystalization

  描述了一种在无溶剂条件下使用碘作为催化剂合成磺酰胺的新颖，快速且环境友好的方案。该方法涉及在使用TBHP作为氧化剂的催化量碘存在下，磺酰肼和胺的氧化偶联。该方案不需要纯化技术，例如柱色谱法和重结晶法。
• Aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20010037039A1

  公开（公告）日：2001-11-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 —R 4 , R 6 —R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula . The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  描述了氨基胍和烷氧基胍化合物，包括式子：1中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在规范中给出，以及其水合物、溶剂化合物或药物可接受的盐，这些化合物抑制蛋白酶酶，如凝血酶。还描述了制备公式化合物的方法。本发明的新型化合物是蛋白酶的有效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性地抑制凝血酶表现出抗血栓活性，或者是用于制备具有抗血栓活性的化合物的中间体。本发明包括一种组合物，用于抑制哺乳动物中的血小板丢失、抑制血小板聚集的形成、抑制纤维蛋白的形成、抑制血栓形成和抑制栓塞形成，包括本发明中的化合物和药物可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液采集、血液循环和血液储存的设备中使用的材料中，如导管、血液透析机、血液采集注射器和管、血液管路和支架。
• Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040002539A1

  公开（公告）日：2004-01-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 -R 4 , R 6 -R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula L The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  本发明涉及氨基胍和烷氧基胍化合物，包括以下式子的化合物：1其中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在说明书中给出，以及其水合物、溶剂合物或药学上可接受的盐，其抑制蛋白酶如凝血酶。还描述了制备式L化合物的方法。本发明的新化合物是蛋白酶的强力抑制剂，尤其是类胰蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种用于抑制哺乳动物体内血小板丧失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物，其中包括本发明中的化合物和药学上可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理链接到用于血液收集、血液循环和血液储存的设备制造中使用的材料中，如导管、血液透析机、血液采集注射器和管道、血液输送管和支架等。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。